All In Biotech

Drug Trial Radar · NCT07507500

Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months

Strategies for Antiplatelet Management Following Acute Coronary Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 8,100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

8,100

Planned (sponsor's estimate)

Start

Sep 2, 2026

Primary completion

Jul 2029

Study completion Jan 2030

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
First posted
Apr 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one. After PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding. This study is not testing any new intervention, rather comparing approved drugs and approved durations of use.

Conditions

  • Myocardial Infarction (MI)

Interventions

  • PrasugrelDrug

    Prasugrel during 12 months

  • TicagrelorDrug

    Ticagrelor plus aspirin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ischemic eventsTime frame: 12 months

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • Mater Private Network Dublin

    Dublin, Ireland · Not yet recruiting

  • Paula Stradiņa klīniskā universitates slimnīca

    Riga, Latvia · Not yet recruiting

  • Oslo University Hospital, Ullevål.

    Oslo, Norway · Not yet recruiting

  • Saint John Paul II Hospital in Cracow

    Krakow, Poland · Not yet recruiting

  • Fundación Jiménez Díaz University Hospital

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.